Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05848713 · ClinicalTrials.gov registry record · Phase 3

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

A Phase 3 study of Community-acquired Pneumonia, sponsored by University of Manitoba.

Recruiting
Registry status
Phase 3
Development phase
4,000
Enrollment target
20
Study locations

NCT05848713 is a Phase 3 study of Community-acquired Pneumonia that is actively recruiting participants, run by University of Manitoba. The registered enrollment target is 4,000 participants, below the 108,677-participant average among 9 other Community-acquired Pneumonia trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05848713, a Phase 3 study of Community-acquired Pneumonia, is actively recruiting participants, sponsored by University of Manitoba.

RECRUITING
Registry status
Phase 3
Development phase
4,000 participants
Enrollment target
20
Study locations

Study Summary

This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).

Conditions Studied

Community-acquired Pneumonia

Interventions

  • DRUG Heparin

Study Locations (20)

Espírito Santo

  • Hospital Estadual Dr. Jayme Santos Neves - Serra
  • Hospital Evangelico de Vila Velha - Vila Velha
  • Hospital Universitário Cassiano Antonio Moraes - Vitória

Federal District

  • Hospital Brasilia - Brasília
  • Hospital Sao Brasilia - Brasília
  • Instituto de Cardiologia e Transplantes do Distrito Federal - Brasília

Goiás

  • Hospital de Messejana Dr. Carlos Alberto Studart Gomes - Goiânia
  • Hospital Ruy Azeredo - Goiânia
  • Instituto Goiano de Oncologia e Hematologia - INGOH - Goiânia

Minas Gerais

  • Hospital Felicio Rocho - Belo Horizonte
  • NUPEC-Orizonti - Belo Horizonte

Paraná

  • Hospital Santa Cruz - Curitiba
  • PUCPR - Curitiba

Illinois

  • University of Chicago - Chicago

Louisiana

  • Ochsner Clinic - Jefferson

Maine

  • Maine Medical Centre - Portland

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2023-10-10
Est. Completion 2029-03-31
Phase Phase 3

Sponsor

University of Manitoba

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05848713

The ClinicalTrials.gov registry entry for NCT05848713 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 108,677-participant average among 9 other Community-acquired Pneumonia trials with a reported enrollment target (96% lower). The listed sponsor is University of Manitoba, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Community-acquired Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Heparin is the first listed.

NCT05848713 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Espírito Santo, Federal District, Goiás.

Frequently Asked Questions

What is clinical trial NCT05848713 about?

NCT05848713 is a clinical study titled "AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia". This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP)...

What is the current status of trial NCT05848713?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,000 participants. The study started on 2023-10-10. Estimated completion is 2029-03-31.

What conditions does trial NCT05848713 study?

This clinical trial studies the following conditions: Community-acquired Pneumonia.

What interventions are being tested in trial NCT05848713?

The interventions under investigation include: Heparin (DRUG).

Who is sponsoring clinical trial NCT05848713?

This trial is sponsored by University of Manitoba, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05848713 being conducted?

This trial has 20 study locations across Illinois, Louisiana, Maine, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Community-acquired Pneumonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Community-acquired Pneumonia

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.